Sophiris Bio Inc (SPHS)

2.07
NASDAQ : Health Care
Prev Close 2.07
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.83 / 8.55
Avg Volume 246.40K
Exchange NASDAQ
Shares Outstanding 30.11M
Market Cap 63.23M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Topsalysin Data From Successful Phase 2a Localized Prostate Cancer Study To Be Presented At The 32nd European Association Of Urology Congress

Poster selected as one of the best in a poster session during the 32nd Annual EAU Congress

First Week of February 17th Options Trading For Sophiris Bio (SPHS)

First Week of February 17th Options Trading For Sophiris Bio (SPHS)

Investors in Sophiris Bio Inc saw new options become available this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPHS options chain for the new February 17th contracts and identified the following put contract of particular interest.

Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital

Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital

Roth Capital initiated coverage of Sophiris Bio (SPHS) stock with a 'buy' rating on Thursday.

Sophiris Bio (SPHS) Stock Tumbles on Public Offering

Sophiris Bio (SPHS) Stock Tumbles on Public Offering

Sophiris Bio (SPHS) announced an offering of common shares and warrants late on Monday.

In the Red, and Breadth Is Steadily Slipping

In the Red, and Breadth Is Steadily Slipping

There is hesitancy to chase, especially with the FOMC rate decision this afternoon.

9-Day Churn Favors Upside Resolution

9-Day Churn Favors Upside Resolution

Tomorrow's FOMC decision is a convenient catalyst for a move.

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sophiris Bio (SPHS) Stock Jumps After Drug Trial Meets Goal

Sophiris Bio (SPHS) Stock Jumps After Drug Trial Meets Goal

Sophiris Bio (SPHS) stock is increasing on heavy trading volume on Wednesday, after the company announced that its prostate drug met the goal of a Phase 3 study.

Sophiris Bio Reports Second Quarter Financial Results

Sophiris Bio Reports Second Quarter Financial Results

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six...

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to soar higher from current levels.

Sophiris Bio To Present At The LD Micro Invitational Conference

Sophiris Bio To Present At The LD Micro Invitational Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E.

Sophiris Bio Enrolls First Patients In Phase 2a Proof Of Concept Prostate Cancer Study

Sophiris Bio Enrolls First Patients In Phase 2a Proof Of Concept Prostate Cancer Study

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that the first patients have been dosed in...

Sophiris Bio Reports First Quarter Financial Results

Sophiris Bio Reports First Quarter Financial Results

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months...

Sophiris Bio To Present At The Needham Healthcare Conference

Sophiris Bio To Present At The Needham Healthcare Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E.

Sophiris Bio Reports Fourth Quarter And Full Year Financial Results

Sophiris Bio Reports Fourth Quarter And Full Year Financial Results

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months and...

5 Stocks Poised for Big Breakouts: Xoom, Alcobra and More

5 Stocks Poised for Big Breakouts: Xoom, Alcobra and More

These stocks look ready to break out and trade higher from current levels.

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

Keep these under-$10 biotech stocks on your breakout trading radar.

Sophiris Bio To Present At The Leerink Global Healthcare Conference

Sophiris Bio To Present At The Leerink Global Healthcare Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E.

Sophiris Bio Reports Administrative Interim Analysis For The

Sophiris Bio Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the...

Sophiris Bio To Present At The 26th Annual Piper Jaffray Healthcare Conference

Sophiris Bio To Present At The 26th Annual Piper Jaffray Healthcare Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for...

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

Sophiris Bio Reports Third Quarter Financial Results

Sophiris Bio Reports Third Quarter Financial Results

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the...

Sophiris Bio To Present At The Stifel 2014 Healthcare Conference

Sophiris Bio To Present At The Stifel 2014 Healthcare Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for...

3 Under-$10 Health Care Stocks Triggering Breakout Trades

3 Under-$10 Health Care Stocks Triggering Breakout Trades

Keep these health care stocks under $10 on your breakout trading radar.